Mirofuril caps. 200mg 20 pieces

Description

Composition
Active substance:
1 capsule contains: nifuroxazide 100 mg or 200 mg.
Excipients:
Sucrose, corn starch, microcrystalline cellulose, magnesium stearate. Capsule shell composition: gelatin, titanium dioxide (E171), yellow iron oxide (100 mg capsule).
Description:
100 mg capsule: Hard gelatin capsules № 2, the housing lid and yellow. Contents of capsules – powder yellow fire yellow powder inclusions in the form of small pieces of the compressed mass, or pressed a yellow powder, which disintegrates under slight pressure.
200 mg capsule: Hard gelatin capsules № 0. body and lid white. Contents of capsules – powder yellow or yellow powder inclusions in the form of small pieces of the compressed mass, or pressed a yellow powder, which disintegrates under slight pressure.
Product form:
Capsules 100 mg or 200 mg.
Package 20, 30, 50 capsules.
Contraindications
Hypersensitivity to nitrofuran derivatives or other components of the formulation; fructose intolerance syndrome glucose-galactose malabsorption, or lack of sucrase and isomaltase. pregnancy; Children under 3 years of age (for a given dosage form).
Dosage
200 mg
Indications
Acute bacterial diarrhea flowing without deterioration in general condition, fever, intoxication.
Interaction with other drugs
No data that nifuroxazide interacts with other drugs. Together with the admission ethanol may develop disulfiramopodobnon reactions (abdominal pain, nausea, vomiting, headache, tachycardia, blurred vision, fatigue, cramps). Not recommended simultaneous application of drugs depressing the function of the central nervous system.
Overdose
The drug is not absorbed from the gastrointestinal tract and does not enter the systemic circulation. Symptoms of overdose are not known. In case of exceeding the dose recommended gastric lavage and symptomatic treatment.
pharmachologic effect
Pharmacological group:
Antimicrobial broad-spectrum nitrofuran.
Pharmacological properties:
Antibacterial.
Pharmacodynamics:
It is assumed that nifuroxazide antimicrobial activity due to the presence in its composition NO2-groups, which cause inhibition of the dehydrogenase activity and gives in the synthesis of proteins of pathogenic bacteria. Does not cause occurrence of drug-resistant strains are also cross-resistance was observed with other antibacterial agents. The efficiency of nifuroxazide is independent of pH, exists in the lumen of the intestine or the sensitivity of microorganisms to antibiotics.
When used in therapeutic doses has a bacteriostatic action, in high – bactericidal.
Highly active against Campylobacter jejuni, Escherichia coli, Salmonella spp, Shigella spp; Clostridium perfringens, Vibrio cholerae, pathogenic Vibrions and Vibrio parahaemolytique, Staphylococcus spp.
Very sensitive to nifuroxazide: Citrobacter spp, Enterobacter cloacae and Proteus indologenes.
Resistant to nifuroxazide: Klebsiella spp, Proteus mirabilis, Providencia spp, Pseudomonas spp..
Nifuroxazide no effect on saprophytic flora, does not disturb the balance of the normal intestinal flora. In acute bacterial diarrhea restoring intestinal eubioz. When infected by viruses enterotropnymi prevents the development of bacterial superinfection.
Pharmacokinetics:
After oral administration nifuroxazide practically not absorbed from the digestive tract and its antibacterial effect has only in the lumen of the intestine. Nifuroxazide output intestine: 20% unchanged and the remainder nifuroxazide – chemically modified.
Pregnancy and breast-feeding
Use in pregnancy is contraindicated. Nifuroxazide is not absorbed from the gastrointestinal tract and does not enter the systemic circulation, but the use of the drug during lactation is possible only under strict indications, it should be to decide on the termination of breastfeeding.
Conditions of supply of pharmacies
Without recipe.
side effects
Allergic reactions (rash, urticaria, angioneurotic edema, anaphylactic shock), nausea, and vomiting.
special instructions
In the treatment of diarrhea in conjunction with therapy nifuroxazide necessary to conduct rehydration therapy (oral or intravenous) in accordance with the condition of the patient and the intensity of diarrhea. It prohibits the use of alcohol during therapy, since it increases the body’s sensitivity to nifuroxazide. When the manifestation of hypersensitivity symptoms (shortness of breath, rash, pruritus) discontinue use of the drug. In the case of bacterial diarrhea with signs of systemic damage (deterioration of general condition, fever, symptoms of intoxication or infection) should consult a doctor to decide on the use of antibacterial drugs with systemic action.
Effects on ability to drive and use machines:
The drug has no effect on psychomotor performance and ability to manage the transport and work with mechanisms.
Storage conditions
In the dark place at a temperature not higher than 25 C.
Keep out of the reach of children.
Dosing and Administration
Inside. Nifuroxazide therapy should not last longer than 7 days.
Capsules 100 mg:
Adults and children over 6 years of drug prescribed to 2 capsules. (200 mg) 4 times a day, daily dose – 800 mg.
Children 3-6 years of drug prescribed to 2 capsules. (200 mg) 3 times a day, daily dose – 600 mg.
200 mg capsules:
Adults and children over 6 years of preparation appoint 1 caps. (200 mg) 4 times a day, daily dose – 800 mg.
Children 3-6 years of preparation appoint 1 caps. (200 mg) 3 times a day, daily dose – 600 mg.
If during the first three days of no improvement, you should seek medical attention.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist